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Abstract
Psoriasis is a common chronic and recurrent inflammatory skin disorder that has been associated with oxidative stress,
abnormal plasma lipid metabolism and with high frequency of cardiovascular events. This prevalence seems to be related to
the severity of psoriasis, as it occurs more frequently in patients presenting large areas of the body affected with psoriasis
lesions. The aim of our work was to evaluate the development of oxidative stress and of dislipidemia in psoriasis, and to look
for a correlation between their levels and worsening of psoriasis. We evaluated lipid profile, total antioxidant capacity,
antioxidant vitamins A and E, and lipoperoxidation products. The study was performed in controls and in patients presenting
mild and severe psoriasis. Patients presented risk changes in lipid profile (a rise in cholesterol (P,0.01), triglycerides
(P,0.001), low density lipoprotein cholesterol (P,0.01), very low density lipoprotein cholesterol (P,0.01), apolipoprotein
B (P,0.001) and lipoprotein(a) (P,0.001); and a reduction in high density lipoprotein cholesterol (P,0.001)), a rise in
lipoperoxidation products (P,0.001) and a reduction in total antioxidant capacity (P,0.001) and in antioxidant vitamins A
(P,0.001) and E (P,0.05). Moreover, we found that the worsening of psoriasis was associated with the enhancement of
oxidative stress and of the lipid risk changes. Our data suggest that psoriasis patients must be considered as a group at risk
for cardiovascular disease and that this risk seems to be higher in severe psoriasis. In addition, a possible benefit of an
enriched diet or of a supplement of vitamins A and E in psoriasis patients should be further studied. Ó 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction present hypertension and an abnormal lipid profile,
namely hypercholesterolemia, hypertriglyceridemia,
Patients at risk for cardiovascular events often high lipoprotein (a), low density lipoprotein choles-
terol and apolipoprotein B concentration, low high
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portant role in the pathophysiology of cardiovascular density lipoprotein cholesterol (VLDLc), apolipo-
diseases (CVD) [1,2]. Activated white blood cells protein AI (Apo AI), apolipoprotein B (Apo B) and
(WBC) are known as important sources of oxygen lipoprotein (a) (Lp(a)). To study the oxidant /anti-
metabolites and proteases that may impose oxidative oxidant balance we evaluated total plasma antioxi-
changes to blood cells and to plasma constituents. dant capacity and total plasma lipoperoxidation
According to the oxidative modification hypothesis products. We also studied as plasma antioxidants the
for atherogenesis, oxygen metabolites contribute to levels of vitamin A and vitamin E.
the progression of the atherosclerotic process by
modifying oxidatively low density lipoprotein
cholesterol.
Increased production of oxygen metabolites is a 2. Materials and methods
common feature of most human diseases [3,4],
including CVD and psoriasis, and usually triggers an
up-regulation of the antioxidant defences. However, 2.1. Subjects
when the antioxidant capacity is overwhelmed an
oxidative stress develops leading to oxidative dam- The protocol used for patients and controls was
age of lipids and proteins. approved by the Committee on Ethics of the Uni-
Psoriasis is a common chronic and recurrent versity Hospital of Coimbra. Patients and controls
inflammatory skin disorder that has been associated included 88 males and females presenting similar
with abnormal plasma lipid metabolism and with ages. The control group included 40 apparently
high frequency of cardiovascular events. This preval- healthy individuals (55% males and 45% females),
ence of cardiovascular events seems to be related to aged 47613 years, with normal hematological and
the severity of psoriasis, considering that it occurs biochemical values, and with normal lipid profile.
much more frequently in patients presenting large The pathological group included 48 individuals (62%
areas of the body affected with psoriasis lesions [5]. males and 38% females), aged 47612 years, 24
The clinically active psoriasis lesions reveal infil- presenting active psoriasis, and 24 presenting inac-
tration of WBC, and several studies report high tive psoriasis, with diagnosed psoriasis from 2 to 50
levels of WBC activation products in the peripheral years before this study. Psoriasis disease was graded
blood of these patients [6,7]. Therefore, psoriasis according to the area of the psoriasis lesions. Half of
patients may present, side by side with an abnormal the patients presented severe psoriasis or active
lipid profile, a depletion in antioxidant defences, a psoriasis (AP), in whom more than 10% of the body
rise in lipid peroxidation (LPO) and an imbalance of area was covered by psoriasis lesions, and the other
oxidants /antioxidants. These changes are all known half of the patients presented mild psoriasis or
as risk factors for cardiovascular events. inactive psoriasis (IP), with less than 10% of the
The aim of our work was to evaluate the lipid body area covered by psoriasis lesions. The body
profile, the total antioxidant capacity as well as some mass index and the ages were similar for both groups
plasma antioxidants, and the total plasma lipoperoxi- of patients and controls.
dation products in a healthy control and in a group of To assess the changes imposed by psoriasis per se,
psoriasis patients. In addition, looking for a correla- none of the patients had received any systemic or
tion between the severity of psoriasis lesions and an local steroid medication or any phototherapy treat-
increased risk for cardiovascular events, we selected ment for at least 1 month prior to blood collection;
for the psoriasis group half of the patients with active none of them had any history of cardiovascular
psoriasis (more than 10% of the body area covered events and none of them presented diabetes mellitus,
by lesions) and the other half with inactive psoriasis a condition that is usually associated with increased
(less than 10% of the body area covered by lesions). plasma lipid levels. In addition, the controls, as well
The study of the lipid profile included the evalua- as the patients, were not receiving any kind of
tion of total cholesterol (Chol), triglycerides (TG), medication, namely antioxidants or vitamins. None
high density lipoprotein cholesterol (HDLc), low of the studied groups were under any dietary restric-
density lipoprotein cholesterol (LDLc), very low tion.
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2.2. Collection and preparation of blood samples Phase Column with UV-detection and subsequent
quantitative determination with the help of an inter-
Blood samples were collected from the subjects, nal standard (Sanofi Pasteur HP 1100).
fasted for 12 h, with and without anticoagulant Total plasma antioxidant capacity was evaluated
(heparin), and centrifuged to obtain plasma and by a colorimetric assay (TAS, Randox Laboratories,
serum, respectively. The recovered serum and plas- UK). Lipid peroxidation was estimated by thiobar-
ma were sequentially analysed. To evaluate vitamin bituric acid reactivity (TBA assay) [9].
A and E light-protected tubes were used to collect
and store the samples. None of the collected samples
was icteric or hemolysed. 2.4. Statistical analysis
The statistical analysis was performed using the2.3. Assays
SPSS package. To evaluate the differences between
groups, we used the Student’s t-test for the de-
2.3.1. Lipid profile terminations presenting a gaussian distribution, and
Serum was used to study the lipid profile. Total the Mann–Whitney test for those presenting a non-
Chol and TG concentrations were measured en- gaussian distribution. A P-value lower than 0.05 was
zymatically using commercially available kits considered statistically significant. The measure-(CHOD-PAP and GPO-PAP, Boehringer, respective- ments are expressed as mean6standard deviation
ly) on an auto-analyser (Hitachi-704-Boeheringer (S.D.).
Mannheim). HDLc was measured (using the method
referred for total Chol) after precipitation of the
lipoproteins that contained Apo B (LDL, VLDL and
Lp(a)) by a phosphotungstic acid magnesium chlo- 3. Results
ride mixture. LDLc was computed by Friedwald’s
formula: LDLc5total Chol2(HDLc1TG/5). We analysed the obtained results in two ways, on
VLDLc was calculated by the formula: VLDLc5 the one hand to study the differences between
TG/5 [8]. Apo AI and Apo B were measured by healthy control and psoriasis patients, and on the
immunonephelometry (Kallestad QM300, Sanofi- other to evaluate the changes in the same studied
Pasteur). Lp(a) was evaluated by an immunotur- parameters according to the activity of the disease
bidimetric assay (Tina-quant, Boehringer Mann- (mild and severe psoriasis).
heim). Table 1 presents the lipid profile found for control
group, for total psoriasis patients (IP1AP) and for IP
2.3.2. Oxidative stress patients and AP patients. When compared to the
The serum samples to measure vitamins A and E control group we found that total psoriasis patients
were stored frozen at 2208C in closed light- (IP1AP) presented significantly higher values for
protected tubes for no more than 24 h after collection Chol (P,0.01), TG (P,0.001), LDLc (P,0.01),
and handled light protected. None of the serum VLDLc (P,0.01), Apo AI (P,0.01), Apo B (P,
samples analysed was icteric or even hemolysed. 0.001), Lp(a) (P,0.001) and for the ratio LDLc/
Vitamin A and E serum levels were evaluated by Chol (P,0.05); significantly lower values were
high performance liquid chromatography (HPLC), found for HDLc (P,0.001) and for the ratio HDLc/
using a commercially available kit (Vitamin A/E by Chol (P,0.001).
HPLC reagent kit, Bio-Rad Lab. GMBH). Serum When comparing the values presented by IP
was mixed with an internal standard. Two phases patients with those presented by the control group we
were developed after the addition of ammonium found significantly higher values of Apo B (P,0.01)
sulphate solution and subsequent centrifugation and Lp(a) (P,0.001); significantly lower values of
(10 0003g /3 min). The upper phase was used HDLc (P,0.05). No significant differences were
immediately for HPLC analysis in an isocratic found in the other studied lipid parameters; however,
system. The samples were separated on a Reversed IP patients showed a trend to increases in Chol, TG,
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Table 1
aLipid profile (mean value6S.D. for each parameter) for control and psoriasis patients
Control IP1AP P-value IP P-value AP P-value P-value
(n540) (n548) IP1AP vs. (n524) IP vs. (n524) AP vs. IP vs. AP
Control Control Control
Chol (mg/dl) 199.8627.7 220.4643.7 ,0.01 208.9647.1 ns 231.8637.6 ,0.001 ,0.05
TG (mg/dl) 92.5627.3 121.0649.3 ,0.001 100.6647.2 ns 141.3643.3 ,0.001 ,0.001
HDLc (mg/dl) 49.963.2 45.365.7 ,0.001 46.866.2 ,0.05 43.764.8 ,0.001 ,0.05
LDLc (mg/dl) 130.9625.2 152.2642.2 ,0.01 143.0644.6 ns 161.4638.5 ,0.001 ns
VLDLc (mg/dl) 18.666.3 24.069.9 ,0.01 20.969.7 ns 27.069.3 ,0.001 ,0.05
Apo AI (mg/dl) 142.2632.9 160.2623.5 ,0.01 155.6621.0 ns 164.8625.3 ,0.01 ns
Apo B (mg/dl) 113.2621.5 133.8627.5 ,0.001 129.3626.7 ,0.01 138.2628.1 ,0.001 ns
Lp(a) (mg/dl) 31.7618.1 63.7640.1 ,0.001 69.5647.1 ,0.001 57.9631.6 ,0.001 ns
HDLc/Chol 0.2660.04 0.2260.06 ,0.001 0.2460.08 ns 0.1960.04 ,0.001 ,0.01
LDLc/Chol 0.6560.05 0.6860.07 ,0.05 0.6760.07 ns 0.6960.06 ,0.01 ns
a Inactive psoriasis — IP; active psoriasis — AP; ns — non-significant.
LDLc, VLDLc, Apo AI and in the ratio LDLc/Chol; 0.001), VLDLc (P,0.05); significantly lower values
a trend to decrease was found in the ratio HDLc/ were observed in HDLc (P,0.05) and in the ratio
Chol. HDLc/Chol (P,0.01). No significant differences
In AP patients we found more pronounced were found in the other studied lipid parameters;
changes, than those presented by IP patients, when however, AP patients showed a trend to increases in
compared to the control group. Moreover, all the LDLc, Apo AI, Apo B, and in the ratio LDLc/Chol,
values presented significant differences: significantly and a trend to reductions in Lp(a).
higher values for Chol (P,0.001), TG (P,0.001), In Table 2 we show the mean values of total
LDLc (P,0.001), VLDLc (P,0.001), Apo AI (P, plasma lipid peroxides (TBA), total plasma anti-
0.01), Apo B (P,0.001), Lp(a) (P,0.001) and for oxidant status (TAS), the balance between them,
the ratio LDLc/Chol (P,0.01); significantly lower and, as plasma antioxidants, the levels of vitamin A
values for HDLc (P,0.001) and for the ratio HDLc/ and vitamin E, for control group, for total psoriasis
Chol (P,0.001). patients (IP1AP), and for IP patients and AP
We have also studied the values according to the patients.
activity of psoriasis, by comparing the values pre- When compared with the control group we found
sented by IP patients to those observed in AP for total psoriasis patients (IP1AP) significantly
patients (Table 1). We found that AP patients higher values for TBA (P,0.001), TBA/TAS (P,
presented higher values of Chol (P,0.05), TG (P, 0.001), TBA/vit A (P,0.001) and for TBA/vit E
Table 2
aLipid peroxidation and antioxidant defences (mean value6S.D. for each parameter) for control and psoriasis patients
Control IP1AP P-value IP P-value AP P-value P-value
(n540) (n548) IP1AP vs. (n524) IP vs. (n524) AP vs. IP vs. AP
Control Control Control
23TBA(310 mM) 1.8560.41 6.1761.21 ,0.001 5.4061.06 ,0.001 6.9560.77 ,0.001 ,0.001
TAS (mM) 1.660.18 1.4160.28 ,0.001 1.5560.21 ns 1.2660.28 ,0.001 ,0.001
vit A (mg/dl) 47.8613.9 17.565.1 ,0.001 16.564.5 ,0.001 18.465.6 ,0.001 ns
vit E (mg/ml) 14.663.8 13.462.5 ,0.05 13.663.0 ns 13.161.9 ,0.05 ns
TBA/TAS 1.1860.31 4.6661.65 ,0.001 3.5460.80 ,0.001 5.7761.52 ,0.001 ,0.001
TBA/vit A 0.04260.02 0.3860.15 ,0.001 0.3560.11 ,0.001 0.42 1 0.17 ,0.001 ,0.05
]
TBA/vit E 0.13560.05 0.4860.14 ,0.001 0.4260.15 ,0.001 0.536 0.10 ,0.001 ,0.01
a Inactive psoriasis — IP; active psoriasis — AP; ns — non-significant.
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(P,0.001); significantly lower values were found for ‘‘oxidative stress conditions’’. Psoriasis as a clinical-
TAS (P,0.001), vit A (P,0.001) and for vit E ly inflammatory skin disease may per se impose an
(P,0.05). oxidative stress condition. The activation of the
In IP patients we observed significantly higher inflammatory cells, resulting in increased leukocyte
values of TBA (P,0.001), TBA/TAS (P,0.001), activation products in the peripheral blood of
TBA/vit A (P,0.001) and of TBA/vit E (P, psoriasis patients, may favour atherogenesis by pro-
0.001); significantly lower values were found for vit moting LDL oxidation. In addition, it is reasonable
A (P,0.001); no significant differences were found that the up-regulation of the antioxidant systems,
for TAS and vit E, though the IP patients showed a triggered by the continuous skin inflammatory pro-
trend towards a decrease in their values. cess, may lead to a decrease in the antioxidant
When comparing the values presented by AP capacity. Therefore, we believe that if psoriasis leads
patients with those presented by the control group, to high levels of oxidants, resulting from leukocyte
we found significantly different values for all the activation and to a reduced antioxidant capacity, then
studied parameters. AP patients presented signifi- psoriasis may favour the atherogenic process. Actu-
cantly higher values, when compared to controls, for ally, the incidence of cardiovascular diseases in
TBA (P,0.001), TBA/TAS (P,0.001), TBA/vit A human populations that have low plasma antioxidant
(P,0.001) and for TBA/vit E (P,0.001); signifi- levels appears to be high, suggesting an important
cantly lower values were found for TAS (P,0.001), role in the progression of atherosclerosis [15–18].
vit A (P,0.001) and for vit E (P,0.05). Cardiovascular events occur frequently in psoriasis
We have also compared the values presented by IP patients, particularly in those patients with a severe
patients to those presented by AP patients (Table 2) pattern and long duration of the disease. Considering
and we found significant differences between them the importance of an altered lipid profile and the
for almost all the studied parameters. We observed development of an oxidative stress condition in
that AP patients presented higher values of TBA atherogenesis, we tried, by evaluating these parame-
(P,0.001), TBA/TAS (P,0.001), TBA/vit A (P, ters in mild and severe psoriasis, to look for a
0.05) and of TBA/vit E (P,0.01). A lower value for correlation between psoriasis and its severity, with a
TAS (P,0.001) was also found. We observed a trend rise in risk factors for cardiovascular diseases and the
to increase in vit A and a trend to decrease in vit E. development of an oxidative stress.
We found that psoriasis patients (IP1 AP) present
a significantly different lipid profile (Table 1), and
4. Discussion that all the observed changes in that profile, except-
ing for Apo AI, are considered as modifications of
Although there have been extensive studies of risk for cardiovascular diseases. Our results (Table
serum lipids and apolipoprotein levels in psoriasis, 2) also suggest that psoriasis is associated with the
their importance in the etiology or in the enhance- development of an oxidative stress, since psoriasis
ment of the disease remains controversial [5,10–12]. patients (IP1AP) presented significantly higher val-
It is accepted that there is a genetic predisposition to ues for TBA, which almost triplicates the value
develop the disease and that several conditions may presented by the control group, and significantly
trigger an enhancement of the disease, with enlarge- lower values for TAS. A significant rise in TBA/
ment of psoriasis lesions, such as infections, skin TAS, TBA/vit A and TBA/vit E ratios shows the
traumas, sunlight, oxidant drugs and stress conditions imbalance between oxidants and antioxidants.
[13,14]. Psoriasis is also frequently associated with The comparative study of the lipid profile and of
some diseases, namely cardiovascular diseases, dia- the oxidative stress between control and each of the
betes mellitus and to rheumatoid arthritis. The role pathologic groups, mild (IP) and severe (AP)
and the importance of these pathologies in the psoriasis (Tables 1 and 2), showed that some signifi-
etiology of psoriasis, or in its enhancement, are still cant atherogenic risk modifications and an imbalance
controversial. It is interesting to notice that these between oxidants and antioxidants are already ob-
commonly associated pathologies are known as served in mild psoriasis, and that in severe psoriasis
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